The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview

Detalhes bibliográficos
Autor(a) principal: Tibiriça,Eduardo
Data de Publicação: 1993
Outros Autores: Bricca,Giampiero, Dontenwill,Monique, Feldman,Josiane, Greney,Hugues, Belcourt,Alain, Stutzmann,Jeanne, Bousquet,Pascal
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Memórias do Instituto Oswaldo Cruz
Texto Completo: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761993000200024
Resumo: Recently, we proposed the hypothesis according to wich the central hypotensive effect of clonidine and related substances could be related to an action upon specific receptors, requiring the imidazoline or imidazoline-like structures, rather than alpha2-adrenoceptors. Since then, direct evidences have been accumulated to confirm the existence of a population of imidazoline specific binding sites in the brainstem of animals and man, more precisely in the Nucleus Reticularis Lateralis (NRL) region of the ventrolateral medulla (VLM), site of the antihypertensive action of clonidine. The purification of the putative endogenous ligand of the imidazoline receptors - named endazoline - is currently being attempted from human brain extracts. This new concept might at last lead to the expected dissociation of the pharmacological mechanisms involved, on the one hand, in the therapeutic antihypertensive effect, and on the other, in their major side-effect, which is sedation. In fact, it has been recently confirmed that hypotension is mediated by the activation of imidazoline preferring receptors (IPR) within the NRL region, while sedation is attributed to the inhibition of alpha2-adrenergic mechanisms in the locus coeruleus, which is involved in the control of the sleep-waking cycle. The IPRmay constitute on interesting target for new drugs in the treatment of arterial hypertension. Finally, dysfunctions of this modulatory system which could be involved in the pathophysiologyof some forms of the hypertensive disease are under investigation.
id FIOCRUZ-4_40fba5b7847d89a90ffbe38e0cfa59a4
oai_identifier_str oai:scielo:S0074-02761993000200024
network_acronym_str FIOCRUZ-4
network_name_str Memórias do Instituto Oswaldo Cruz
spelling The imidazoline receptors and the central regulation of the arterial blood pressure: a minireviewclonidinerilmenidineimidazoline-preferring receptorsnucleus reticularis lateralisarterial hypotensionantihypertensive drugscentral nervous systemRecently, we proposed the hypothesis according to wich the central hypotensive effect of clonidine and related substances could be related to an action upon specific receptors, requiring the imidazoline or imidazoline-like structures, rather than alpha2-adrenoceptors. Since then, direct evidences have been accumulated to confirm the existence of a population of imidazoline specific binding sites in the brainstem of animals and man, more precisely in the Nucleus Reticularis Lateralis (NRL) region of the ventrolateral medulla (VLM), site of the antihypertensive action of clonidine. The purification of the putative endogenous ligand of the imidazoline receptors - named endazoline - is currently being attempted from human brain extracts. This new concept might at last lead to the expected dissociation of the pharmacological mechanisms involved, on the one hand, in the therapeutic antihypertensive effect, and on the other, in their major side-effect, which is sedation. In fact, it has been recently confirmed that hypotension is mediated by the activation of imidazoline preferring receptors (IPR) within the NRL region, while sedation is attributed to the inhibition of alpha2-adrenergic mechanisms in the locus coeruleus, which is involved in the control of the sleep-waking cycle. The IPRmay constitute on interesting target for new drugs in the treatment of arterial hypertension. Finally, dysfunctions of this modulatory system which could be involved in the pathophysiologyof some forms of the hypertensive disease are under investigation.Instituto Oswaldo Cruz, Ministério da Saúde1993-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761993000200024Memórias do Instituto Oswaldo Cruz v.88 n.2 1993reponame:Memórias do Instituto Oswaldo Cruzinstname:Fundação Oswaldo Cruzinstacron:FIOCRUZ10.1590/S0074-02761993000200024info:eu-repo/semantics/openAccessTibiriça,EduardoBricca,GiampieroDontenwill,MoniqueFeldman,JosianeGreney,HuguesBelcourt,AlainStutzmann,JeanneBousquet,Pascaleng2020-04-25T17:47:09Zhttp://www.scielo.br/oai/scielo-oai.php0074-02761678-8060opendoar:null2020-04-26 02:05:40.245Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruztrue
dc.title.none.fl_str_mv The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview
title The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview
spellingShingle The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview
Tibiriça,Eduardo
clonidine
rilmenidine
imidazoline-preferring receptors
nucleus reticularis lateralis
arterial hypotension
antihypertensive drugs
central nervous system
title_short The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview
title_full The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview
title_fullStr The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview
title_full_unstemmed The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview
title_sort The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview
author Tibiriça,Eduardo
author_facet Tibiriça,Eduardo
Bricca,Giampiero
Dontenwill,Monique
Feldman,Josiane
Greney,Hugues
Belcourt,Alain
Stutzmann,Jeanne
Bousquet,Pascal
author_role author
author2 Bricca,Giampiero
Dontenwill,Monique
Feldman,Josiane
Greney,Hugues
Belcourt,Alain
Stutzmann,Jeanne
Bousquet,Pascal
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Tibiriça,Eduardo
Bricca,Giampiero
Dontenwill,Monique
Feldman,Josiane
Greney,Hugues
Belcourt,Alain
Stutzmann,Jeanne
Bousquet,Pascal
dc.subject.por.fl_str_mv clonidine
rilmenidine
imidazoline-preferring receptors
nucleus reticularis lateralis
arterial hypotension
antihypertensive drugs
central nervous system
topic clonidine
rilmenidine
imidazoline-preferring receptors
nucleus reticularis lateralis
arterial hypotension
antihypertensive drugs
central nervous system
dc.description.none.fl_txt_mv Recently, we proposed the hypothesis according to wich the central hypotensive effect of clonidine and related substances could be related to an action upon specific receptors, requiring the imidazoline or imidazoline-like structures, rather than alpha2-adrenoceptors. Since then, direct evidences have been accumulated to confirm the existence of a population of imidazoline specific binding sites in the brainstem of animals and man, more precisely in the Nucleus Reticularis Lateralis (NRL) region of the ventrolateral medulla (VLM), site of the antihypertensive action of clonidine. The purification of the putative endogenous ligand of the imidazoline receptors - named endazoline - is currently being attempted from human brain extracts. This new concept might at last lead to the expected dissociation of the pharmacological mechanisms involved, on the one hand, in the therapeutic antihypertensive effect, and on the other, in their major side-effect, which is sedation. In fact, it has been recently confirmed that hypotension is mediated by the activation of imidazoline preferring receptors (IPR) within the NRL region, while sedation is attributed to the inhibition of alpha2-adrenergic mechanisms in the locus coeruleus, which is involved in the control of the sleep-waking cycle. The IPRmay constitute on interesting target for new drugs in the treatment of arterial hypertension. Finally, dysfunctions of this modulatory system which could be involved in the pathophysiologyof some forms of the hypertensive disease are under investigation.
description Recently, we proposed the hypothesis according to wich the central hypotensive effect of clonidine and related substances could be related to an action upon specific receptors, requiring the imidazoline or imidazoline-like structures, rather than alpha2-adrenoceptors. Since then, direct evidences have been accumulated to confirm the existence of a population of imidazoline specific binding sites in the brainstem of animals and man, more precisely in the Nucleus Reticularis Lateralis (NRL) region of the ventrolateral medulla (VLM), site of the antihypertensive action of clonidine. The purification of the putative endogenous ligand of the imidazoline receptors - named endazoline - is currently being attempted from human brain extracts. This new concept might at last lead to the expected dissociation of the pharmacological mechanisms involved, on the one hand, in the therapeutic antihypertensive effect, and on the other, in their major side-effect, which is sedation. In fact, it has been recently confirmed that hypotension is mediated by the activation of imidazoline preferring receptors (IPR) within the NRL region, while sedation is attributed to the inhibition of alpha2-adrenergic mechanisms in the locus coeruleus, which is involved in the control of the sleep-waking cycle. The IPRmay constitute on interesting target for new drugs in the treatment of arterial hypertension. Finally, dysfunctions of this modulatory system which could be involved in the pathophysiologyof some forms of the hypertensive disease are under investigation.
publishDate 1993
dc.date.none.fl_str_mv 1993-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761993000200024
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761993000200024
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0074-02761993000200024
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Oswaldo Cruz, Ministério da Saúde
publisher.none.fl_str_mv Instituto Oswaldo Cruz, Ministério da Saúde
dc.source.none.fl_str_mv Memórias do Instituto Oswaldo Cruz v.88 n.2 1993
reponame:Memórias do Instituto Oswaldo Cruz
instname:Fundação Oswaldo Cruz
instacron:FIOCRUZ
reponame_str Memórias do Instituto Oswaldo Cruz
collection Memórias do Instituto Oswaldo Cruz
instname_str Fundação Oswaldo Cruz
instacron_str FIOCRUZ
institution FIOCRUZ
repository.name.fl_str_mv Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruz
repository.mail.fl_str_mv
_version_ 1669937661456941056